GRPR and breast carcinoma: 111In-AMBA (111In t1/2 = 2.8 days) is a GRPR agonist that has been tested in an autoradiography study of 50 human breast cancer tissue specimens, with 96% (48/50) of them showing elevated GRPR levels (Dalm et al., 2015).